Belite Bio Gestione

Gestione criteri di controllo 2/4

Belite Bio Il CEO è Tom Lin, nominato in Nov2021, ha un mandato di 6.67 anni. possiede direttamente 1.72% delle azioni della società, per un valore di $ 42.66M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3 anni e 3 anni.

Informazioni chiave

Tom Lin

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	3yrs
Proprietà del CEO	1.7%
Durata media del management	3yrs
Durata media del Consiglio di amministrazione	3yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Sep 26

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

Jul 03

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Mar 20

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Jan 10

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

Jul 31

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

May 03

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

AMMINISTRATORE DELEGATO

Tom Lin (45 yo)

3yrs

Mandato

Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio Inc since March 2018 and its Chairman and served as the Chief Executive Officer since November...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Yu-Hsin Lin	Chairman of the Board of Directors & CEO	3yrs	Nessun dato	1.72% $ 42.7m
Hao-Yuan Chuang	CFO & Director	4.6yrs	Nessun dato	1.01% $ 25.0m
Nathan Mata	Chief Scientific Officer	3yrs	Nessun dato	Nessun dato
Hendrik Scholl	Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board	less than a year	Nessun dato	Nessun dato

3.0yrs

Durata media

45yo

Età media

Gestione esperta: Il team dirigenziale di BLTE è considerato esperto (durata media dell'incarico 3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yu-Hsin Lin	Chairman of the Board of Directors & CEO	6.7yrs	Nessun dato	1.72% $ 42.7m
Hao-Yuan Chuang	CFO & Director	3yrs	Nessun dato	1.01% $ 25.0m
Hendrik Scholl	Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board	no data	Nessun dato	Nessun dato
Frank Holz	Member of Ophthalmology Clinical Advisory Board	no data	Nessun dato	Nessun dato
Yuan Lu	Independent Director	2.6yrs	Nessun dato	Nessun dato
Quan Dong Nguyen	Member of Ophthalmology Clinical Advisory Board	no data	Nessun dato	Nessun dato
Michel Michaelides	Member of Ophthalmology Clinical Advisory Board	no data	Nessun dato	Nessun dato
Wan-Shan Chen	Director	3yrs	Nessun dato	Nessun dato
Hung-Wei Chen	Director	3yrs	Nessun dato	Nessun dato
John Longo	Independent Director	2.6yrs	Nessun dato	Nessun dato
Gary Biddle	Independent Director	2.6yrs	Nessun dato	Nessun dato
Robyn Guymer	Member of Ophthalmology Clinical Advisory Board	no data	Nessun dato	Nessun dato

3.0yrs

Durata media

45yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BLTE sono considerati esperti (durata media dell'incarico 3 anni).

Belite Bio Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Key Executive notifies of intention to sell stock

Director notifies of intention to sell stock

Belite Bio Announces Appointment of Hendrik P. N. Scholl as Chief Medical Officer

Key Executive notifies of intention to sell stock

CFO & Director notifies of intention to sell stock

Director notifies of intention to sell stock

Recent updates

Price target increased by 18% to US$66.75

Key Executive notifies of intention to sell stock

We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Director notifies of intention to sell stock

Belite Bio Announces Appointment of Hendrik P. N. Scholl as Chief Medical Officer

Key Executive notifies of intention to sell stock

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

CFO & Director notifies of intention to sell stock

Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio, Inc has filed a Follow-on Equity Offering in the amount of $24.999964 million.

Director notifies of intention to sell stock

Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Chief Scientific Officer notifies of intention to sell stock

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

CFO & Director notifies of intention to sell stock

Director notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

New minor risk - Shareholder dilution

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

New major risk - Share price stability

Price target decreased by 21% to US$45.67

Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga

Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease

Belite Bio, Inc to Report Q1, 2023 Results on May 10, 2023

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio, Inc Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

Less than half of directors are independent

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Belite Bio, Inc Presents 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease At AAO Annual Meeting 2022

Belite Bio Receives Approval of Lbs-008 Phase 3 Clinical Trial in China

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of Lbs-008 in Stargardt Disease in the U.S

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Belite Bio, Inc to Report Q2, 2022 Results on Aug 10, 2022

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Belite Bio, Inc Submits Investigational New Drug Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Belite Bio, Inc Presents Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

Belite Bio Receives FDA Fast Track Designation For LBS-008

No independent directors

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media